Findings showed treatment with Rybrevant plus chemotherapy significantly reduced the risk of disease progression or death by 52% compared with chemotherapy.
New longer-term data from the MARIPOSA study confirm superior outcomes of amivantamab plus lazertinib regimen compared to osimertinib monotherapy as first-line therapy1 Results from an interim ...